Navigation Links
Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
Date:3/30/2011

liver patients in Japan. We strongly believe that OCA has the potential to significantly add to the treatment options DSP can make available to these patients and are looking forward to working with Intercept to bring OCA to the market as an important new therapy for PBC and the first drug approved for NASH."

"This agreement is an important milestone for our OCA program and provides additional confirmation of our drug's potential," said Mark Pruzanski, MD, President and CEO of Intercept. "We are excited to be partnering in Asia with DSP, given its proven track record in the development and commercialization of drugs in the hepatology area. This collaboration with DSP will provide important development support as we advance OCA in parallel for PBC, NASH and possibly other indications."

About Obeticholic Acid (OCA or INT-747)

OCA is a potent, first-in-class farnesoid X receptor (FXR) agonist derived from the primary human bile acid chenodeoxycholic acid, the natural endogenous FXR agonist.  Intercept has previously announced positive Phase II results from randomized clinical trials in patients with primary biliary cirrhosis (PBC) and in type 2 diabetics with nonalcoholic fatty liver disease.  The clinical data and mechanism of action support OCA's potential as a novel, hepatoprotective agent in a broad range of chronic liver diseases.  

About Primary Biliary Cirrhosis (PBC)

PBC is the most common autoimmune chronic liver disease that primarily afflicts women over the age of 40. PBC causes substantial loss of intrahepatic bile ducts, resulting in impaired bile flow (cholestasis) and progressive fibrosis that leads eventually to cirrhosis. It is estimated that there are approximately 50,000 PBC patients in Japan and more than 400,000 in China.  Given inadequate treatment options, up to 50% of such patients worldwide continue to be at significant risk of progression to liver transplant or death.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
2. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
3. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
4. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
5. Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
6. Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011
7. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
8. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
9. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
10. New Survey Emphasizes Value of Biopharmaceutical Company Engagement With Healthcare Providers
11. LodgeNet Healthcare Partners With American Society of Health-System Pharmacists to Improve Clinical Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 After 6 months of careful ... here - the new programme for the next Cool Chain ... our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and ... that is broad and yet specific, focused and yet accessible, ...
(Date:9/18/2014)... Calif. , Sept. 18, 2014   ... ), a biopharmaceutical company leading the discovery and ... it has initiated its ATHENA natural history of ... life-threatening genetic kidney disease with no approved therapy. ... natural decline of renal function markers such as ...
(Date:9/18/2014)... , Sept. 18, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that the ... Geert Cauwenbergh , will present at ... Conference on Wednesday, September 24, 2014 at ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... MADISON, N.J., March 28, 2011 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today it ... subsidiary, Spark Acquisition Corporation, for all of the outstanding ... (Nasdaq: CRA ), one of the world,s ...
... (Nasdaq: VRUS ) today announced that it will ... Study of the Liver (EASL) on Saturday, April 2, 2011 ... Pharmasset,s progress on the programs that are the subject of ... a simultaneous webcast of this event via the internet, log ...
Cached Medicine Technology:Quest Diagnostics Commences Tender Offer for Acquisition of Celera 2Quest Diagnostics Commences Tender Offer for Acquisition of Celera 3Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 Clinical ... provides data on the Edema clinical trial scenario. This ... clinical trials on Edema. It includes an overview of ... the site of trial conduction across the globe. The ... by their phase, trial status, prominence of the sponsors ...
(Date:9/18/2014)... Springs, LA (PRWEB) September 18, 2014 This past ... got a kiss from Roy at the kissing booth during the ... “Bo” Bryant Animal Shelter. “I have loved animals my whole ... with most of those animals being strays who needed a home. ... animals since I can’t take them all home!” , The CEO ...
(Date:9/18/2014)... Cary, NC (PRWEB) September 18, 2014 Relias ... the health and human services markets, today announced it has ... the fastest growing private companies in America. , In the ... growth, and moved up almost 2,000 spots on the Inc. ... in 2012. , “The industries we serve continue ...
(Date:9/18/2014)... Schaumburg, IL (PRWEB) September 18, 2014 ... proving itself a boon to contractors and homeowners ... construction dust that overtakes the home, causes potential ... project. Now available nationwide, the BuildClean system allows ... from demolition, sanding and other standard remodeling tasks. ...
(Date:9/18/2014)... Maureen Salamon HealthDay ... -- Migraines in midlife may be associated with increased ... in later years, new research suggests. The study, ... two brain-based conditions, also suggested that the migraine-Parkinson,s association ... An aura is a warning sign of a pending ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3
... KENILWORTH, N.J., July 24 Schering-Plough Corporation (NYSE: ... Court approval, to resolve litigation seeking to enjoin the planned ... relief. The consolidated class action lawsuits, previously reported in ... in U.S. District Court for the District of New Jersey. ...
... , , , ... ( www.medworksusa.org ) will provide free access for the uninsured ... a.m. to 4 p.m. Saturday and Sunday, July 25 and 26, at ... mass health clinic sponsored by MedWorks and will provide 1100 medical, 300 ...
... WASHINGTON, July 24 Medicine and healing have long been ... years, the debate about the nature of the relationship between ... book, "Spirituality and Medicine: Can the Two Walk Together?" ( ... Ph.D., J.D., M.Div., and Harold B. Betton, M.D., Ph.D., offer ...
... LINTHICUM, Md., July 24 Dialysis Corporation of America (Nasdaq: ... second quarter 2009 financial results on Wednesday August 5, 2009, after ... conference call in conjunction with its second quarter 2009 earnings release ... , , Those interested in ...
... Foundation Radiology Group (FRG), the premier provider of diagnostic imaging ... the addition of Jim Yamshak, Senior Vice President of Sales, ... , , Jim Yamshak, a ... to the FRG team. Most recently, Mr. Yamshak served as ...
... ARBOR, Mich., July 24 As the economy continues to falter, a ... to spend what money they have, and children -- especially those who ... more at risk because of it. , , ... in May 2009 shows 44 percent of families, financial situations have worsened ...
Cached Medicine News:Health News:Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck 2Health News:U.S. Senator Sherrod Brown to Lend Support at MedWorks' Free Medical Clinic This Weekend 2Health News:'Spirituality and Medicine: Can the Two Walk Together?' 2Health News:Dialysis Corporation of America Announces Second Quarter 2009 Earnings Release Date 2Health News:Foundation Radiology Group Builds Sales and Marketing Teams for Projected Record-Year Growth 2Health News:Foundation Radiology Group Builds Sales and Marketing Teams for Projected Record-Year Growth 3Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 2Health News:Recession Stressful for Many Kids, Toughest on Poor and Uninsured 3
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: